Multiple Myeloma Clinical Trial
Official title:
Research Evaluation of PET/MR and PET/CT Imaging for Bone Marrow Lesions
Developing an MRI protocol at 1.5 T allowing quantification of the hematopoietic, fatty and
trabecular moieties of marrow. An ideal protocol would differentiate red marrow from
neoplastic cellular infiltration, and detect loss of trabecular bone. This study assesses
the feasibility of a multiple gradient echo sequence for differentiation of water and fat
constituents of marrow, combined with T2* mapping to interrogate the trabecular component
The investigators hypothesize that these techniques will allow better identification of
lesion type than routine MR sequences, and can be used to quantitatively characterize
myelomatous marrow replacement, with iliac crest biopsy (which is routinely performed in the
diagnosis of myeloma) as gold standard.
Fluoro-deoxyglucose (FDG)/PET CT imaging can detect FDG uptake in active myeloma and is
obtained routinely for certain cohorts of patients with myeloma. PET/CT is commonly used in
both initial whole body assessment and in monitoring remission. PET has been found to be
about 59% sensitive and 75% specific for detection of myeloma .
Myelomatous lesions are detected on MRI by the replacement of marrow fat. Routine MRI
however is limited by scope/field of view, usually evaluating marrow in a single anatomic
region (such as an extremity, the pelvis or spine). To assess the diffuse marrow involvement
in MM, whole body MRI imaging potentiates near global assessment of the marrow, which aids
in evaluating tumor burden, and may be useful in staging.
Imaging of the pelvis and bilateral femora at 1.5 Tesla in a 30 minute research time "slots"
at NYU-FPO MRI, Tisch Hospital, NYU Medical Center, Department of Radiology, HCC basement.
This protocol utilizes routine, Dixon sequences and multi-echo MR "spectroscopic" sequences,
allowing quantization of the fat water and trabecular moieties of marrow. The opposed phase
portion of a Dixon sequence can aid differentiation between dense red marrow and a
metastatic deposits by assaying for intravoxel fat. Diffusion sequences may also potentially
improve specificity by assessing mobility of water in hypercellular and hypocellular
portions of marrow, and will be added to the protocol if scan time permits.
The new sequences conform to FDA safety regulations regarding static magnetic field, time
varying magnetic fields, specific absorption rate, and acoustic noise levels. However, since
they have not been fully validated for diagnostic accuracy, the resulting images will be
analyzed for research purposes only and will not be used in the patient's diagnostic
assessment.
;
Observational Model: Case-Only, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05027594 -
Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT02412878 -
Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma
|
Phase 3 | |
| Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05971056 -
Providing Cancer Care Closer to Home for Patients With Multiple Myeloma
|
N/A | |
| Recruiting |
NCT05243797 -
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
|
Phase 3 | |
| Active, not recruiting |
NCT04555551 -
MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma
|
Phase 1 | |
| Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
| Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
| Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
| Completed |
NCT02916979 -
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
|
Phase 1 | |
| Recruiting |
NCT03570983 -
A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion
|
Phase 2 | |
| Completed |
NCT03665155 -
First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody
|
Phase 1/Phase 2 | |
| Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
| Completed |
NCT02812706 -
Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05024045 -
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
|
Phase 1 | |
| Active, not recruiting |
NCT03989414 -
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03792763 -
Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients
|
Phase 2 | |
| Withdrawn |
NCT03608501 -
A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation
|
Phase 2 | |
| Recruiting |
NCT04537442 -
Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT02546167 -
CART-BCMA Cells for Multiple Myeloma
|
Phase 1 |